Karyopharm Prelim Q4, Commercial Update Disappoints

 - Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 --

-- XPOVIO® (selinexor) Unaudited Net Product Sales of between $20.0 Million and $20.5 Million for Fourth Quarter 2020 and between $76.0 Million and $76.5 Million for the Full Year 2020 --

-- Commercial Launch of XPOVIO in Expanded Multiple Myeloma Indication Fully Underway --

https://www.prnewswire.com/news-releases/karyopharm-announces-preliminary-unaudited-fourth-quarter-and-full-year-2020-total-revenues-and-provides-commercial-update-301204826.html